Spectris AD™

Spectris AD™

Spectris AD™ is a non-invasive disease modifying neuromodulation therapy designed to slow cognitive decline and enhance brain function in patients with Alzheimer’s disease and other neurodegenerative disorders. Developed by Cognito Therapeutics, Spectris AD™ delivers precision-tuned light and sound stimulation at gamma frequencies (40Hz), which has been shown to boost neural activity, reduce neuroinflammation, and promote brain health.Backed by groundbreaking research from MIT and leading clinical studies, Spectris AD™ is an FDA Breakthrough Device currently in pivotal trials. It is designed to be easy to use at home, offering a safe, drug-free alternative for patients and caregivers. By harnessing AI-powered adaptive stimulation, Spectris AD™ tailors treatment to individual patient needs, maximizing therapeutic benefits.
Cognito Therapeutics’ innovative approach represents a paradigm shift in Alzheimer’s treatment, addressing disease progression at its root rather than merely managing symptoms. With the potential to transform neurodegenerative care, Spectris AD™ is paving the way for a new era of personalized brain health solutions.

Share this speaker
Share This Speaker
  • Organization
    Cognito Therapeutics
  • Profession
    Non-invasive treatment for Alzheimer’s disease